{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:02:29Z","timestamp":1788498149850,"version":"build-2803163510"},"reference-count":25,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor. Lung cancer patients with ALK and EML4 fusions respond significantly to ALK inhibitors. The EML4-ALK fusion gene mutation is the result of an inversion of chromosome 2, which juxtaposes the 5 end of the EML4 gene with the 3 end of the ALK gene. In SCLC, the frequency of fusion genes is very low, and to the best of our knowledge, only four cases of ALK fusion gene mutations in SCLC have been reported. In this report, we describe the treatment of a 74-year-old female patient with SCLC who developed recurrence of hilar lymph node metastasis three years after surgical resection. Postoperative NGS showed that this patient is a SCLC patient harboring a rare EML4-ALK fusion mutation, and a satisfactory 43-month overall survival (OS) was achieved after treatment with ensartinib targeting the EML4-ALK fusion gene mutation. The ALK-TKI may be a new treatment option for these patients. This article provides a therapeutic reference.<\/jats:p>","DOI":"10.3390\/curroncol32030163","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:18:32Z","timestamp":1741839512000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Recurrent Small Cell Lung Carcinoma Harboring an EML4\u2013ALK Fusion Mutation with Sustained Response to Ensartinib: A Case Report"],"prefix":"10.3390","volume":"32","author":[{"given":"Hao","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.semcancer.2022.05.010","article-title":"Molecular subtyping of small cell lung cancer","volume":"86","author":"Liang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","article-title":"Overcoming Chemotherapy Resistance in SCLC","volume":"16","author":"Herzog","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Grenda, A., Krawczyk, P., Obara, A., Gajek, \u0141., \u0141om\u017ca-\u0141aba, A., and Milanowski, J. (2024). Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC). Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084208"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3892\/ol.2022.13397","article-title":"EML4-ALK fusion gene in non-small cell lung cancer","volume":"24","author":"Lei","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: A narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/CMAR.S229217","article-title":"Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study","volume":"12","author":"Shi","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_9","unstructured":"(2024, May 25). NCCN Clinical Practice Guidelines in Oncology-Small Cell Lung Cancer (2024(1). Version 2). Available online: http:\/\/www.nccn.org."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2019.11.002","article-title":"PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors","volume":"139","author":"Li","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.2147\/OTT.S323700","article-title":"ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report","volume":"14","author":"Sun","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/JTO.0b013e3182762bcb","article-title":"First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component","volume":"7","author":"Toyokawa","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1016\/j.cllc.2021.03.012","article-title":"A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib","volume":"22","author":"Shen","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.lungcan.2013.05.022","article-title":"An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene","volume":"81","author":"Toyokawa","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.resinv.2014.06.005","article-title":"Anaplastic lymphoma kinase rearrangement in lung cancer: Its biological and clinical significance","volume":"52","author":"Toyokawa","year":"2014","journal-title":"Respir. Investig."},{"key":"ref_16","first-page":"Cd011917","article-title":"Surgery for limited-stage small-cell lung cancer","volume":"4","author":"Barnes","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/jcrt.jcrt_1842_22","article-title":"Progress in the knowledge on the transformation of lung adenocarcinoma to small-cell lung cancer","volume":"19","author":"Wang","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nature12930","article-title":"Alveolar progenitor and stem cells in lung development, renewal and cancer","volume":"507","author":"Desai","year":"2014","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.4161\/cc.10.16.17012","article-title":"Characterization of the cell of origin for small cell lung cancer","volume":"10","author":"Park","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lin, C., Song, H., Huang, C., Yao, E., Gacayan, R., Xu, S.M., and Chuang, P.T. (2012). Alveolar type II cells possess the capability of initiating lung tumor development. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0053817"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2022.05.002","article-title":"Neuroendocrine transformation from EGFR\/ALK-wild type or TKI-na\u00efve non-small cell lung cancer: An under-recognized phenomenon","volume":"169","author":"Chu","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jtho.2015.12.105","article-title":"Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.21.01639","article-title":"Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer","volume":"40","author":"Bogart","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1111\/1759-7714.13716","article-title":"Combined small cell lung carcinoma harboring ALK rearrangement: A case report and literature review","volume":"11","author":"Niitsu","year":"2020","journal-title":"Thorac. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:52:48Z","timestamp":1760028768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030163"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030163","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}